Aligos cuts another 10% of its workforce in reprioritization for NASH and Covid pipelines
NASH and Covid-focused Aligos Therapeutics announced that it is reorganizing its pipeline and cutting around 10% of its staff to extend its cash resources through the end of 2024.
In all, there’s been a 25% reduction in the overall workforce at Aligos since the beginning of 2022, according to the company. As of Sept. 30, 2022, Aligos had 89 full-time employees, including 72 employees in research and development, according to SEC filings.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.